ETS-targeted therapy: can it substitute for MEK inhibitors?
Abstract Background The RAS/MAPK pathway has been intensively studied in cancer. Constitutive activation of ERK1 and ERK2 is frequently found in cancer cells from a variety of tissues. In clinical practice and clinical trials, small molecules targeting receptor tyrosine kinases or components in the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-05-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40169-017-0147-4 |